Pfizer begins phase III trial for vaccine against RSV

On the day after Bavarian Nordic received the promising results from the phase II trial for its vaccine against the RS virus, Pfizer announces its own vaccine candidate entering phase III.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN

US pharmaceutical giant Pfizer enters phase III with its vaccine candidate against the RS virus, the company announces in a press release today.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading